BioNeutral Group, Inc. ("BioNeutral") (OTC Bulletin Board: BONU - News), a chemical technology-based Life Science company announced today that at ATS Labs, using a Quantitative Disk Carrier test starting with 5.5 million Clostridium Difficile (C.diff) spores, BioNeutral's Ygiene(TM) Hospital Grade antimicrobial delivered an amazing 99.9997% kill.
Clostridium Difficile, an extremely dangerous and difficult to eradicate spore, is associated with hospital acquired infections which results in diverted health care providers' efforts, millions of dollars in extra health care expenses, and tens of thousands of unnecessary deaths annually in the United States alone. The best high powered antimicrobial currently used in hospitals as a disinfectant is based upon quaternary ammonium compounds which are ineffective at eradicating Clostridium Difficile spores, resulting in a serious unmet need in the health care arena.
According to Wyeth, a global leader in pharmaceuticals and consumer healthcare products, in the United States, hospital-acquired infections alone afflict nearly 2 million patients and kill approximately 90,000 people annually, more than diabetes or influenza/pneumonia.
About 70% of these hospital-acquired infections are resistant to at least one drug and nosocomial infections, which costs U.S. society between $4 billion and $5 billion annually.
Dr. Andrew Kielbania, Chief Scientist at BioNeutral, stated, "At BioNeutral we have raised the bar in terms of developing superior antimicrobial formulations. Clostridium Difficile spores represents a significant health threat and also is one of the most difficult to eradicate spores in the heath care area. These impressive independent lab pre-testing results not only validate our internal results but also give us great confidence that our ongoing EPA registration of our Ygiene(TM) Hospital Grade Antimicrobial will be successful with an ultimate 100% total kill."
Stephen J. Browand, BioNeutral Group Inc. CEO stated, "We are very encouraged by these first pre-testing results of our Hospital Grade formulation that will undoubtedly save many lives and protect countless others from being exposed to a hospital acquired infection. To have a non-toxic, non-corrosive disinfectant that can kill the very resilient C.diff spore is truly an amazing scientific breakthrough. The fact that it is also environmentally friendly makes it a groundbreaking event."
To complement its internal Ygiene(TM) research and development efforts, BioNeutral frequently uses highly recognized independent laboratories such as ATS Labs of Eagan, MN. In developing superior Ygiene(TM) antimicrobial formulations BioNeutral also uses testing protocols which place an extra and extreme demand on the antimicrobial formulation.
About ATS Labs: ATS Labs is a leading internationally recognized lab used by the developers and users of antimicrobial products. They provide comprehensive antimicrobial service and their superior client service and scientific data have earned them a distinguished record of acceptance with regulatory agencies in the United States, Canada and worldwide.
About BioNeutral Group, Inc.
Headquartered at the New Jersey Institute of Technology/EDC in Newark, New Jersey, BioNeutral Group, Inc., is a chemical technology-based Life Science company that intends to commercialize a combinational chemistry-based technology which can neutralize harmful environmental contaminants, toxins and dangerous micro-organisms including bacteria, viruses, mold, fungi and spores. The formulations, including Ygiene(TM) and Ogiene(TM), which are eco-friendly and include natural and common ingredients which are found in baby products and in every day foods. BioNeutral has combined these widely-used compounds in highly specialized ways to create products that dramatically enhance disinfecting and cleaning results; products include BioNeutralizers and ChemoNeutralizers. BioNeutral's proprietary platform technology has been proven effective in surface, water and airborne applications.
More information about the Company may be found at www.bioneutralgroup.com.
Forward-Looking Statements
BioNeutral routinely tests its formulations against those of its competitors. The results are published to let shareholders know how BioNeutral's technology compares with known formulations in the market place. Any product claim for antimicrobial activity requires approval from the EPA or FDA, depending upon where and how the formulations are used. The EPA and FDA have not reviewed or confirmed the BioNeutral's data and findings. BioNeutral's antimicrobial formulations will be marketed under the brand name Ygiene(TM) and are not yet available for sale in the United States.
Contact Information
BioNeutral Group Inc.
Stephen J. Browand, President and CEO
steve@bioneutralgroup.com
Investor Relations
Aimee Boutcher
973 239-2878
aboutcher@aol.com
